19-DEFORMYL-4'-DEOXYDESMYCOSIN (TMC-01 6) : SYNTHESIS AND BIOLOGICAL PROPERTIES OF
Mycinamicins, a group of macrolides lacking the aldehyde group, have been isolated from fermentations by other workers in our laboratory2) and have shown higher antibacterial activity than other clinically used macrolide antibiotics. Recently, a large number of derivatives of desmycosin and tylosin have been reported and some biological improvements have been made, especially by modification of the aldehyde function3~5). Wehave reported deformylation of the aldehyde moiety of desmycosin by utilizing Wilkinson's catalyst ((Ph3P)3RhCl)3:> and noted an improvement in its biological activities.
Wenow report the synthesis and biological properties of a novel macrolide antibiotic, 19-deformyl-4/-deoxydesmycosin.
Experim ental
General Methods MP's were not corrected. Optical rotations were determined with a Horiba SEPA-200 polarimeter. UVand IR spectra were recorded on Shimadzu UV-365 and Hitachi 260-50 IR spectrometers, respectively. NMRspectra were measured in CDC13using Jeol FX-90 and GSX-400spectrometers, with TMSas an internal standard. Mass spectra were obtained with a Jeol JMS-D300mass spectrometer. Column chromatography was performed on Silica gel 60 (Merck, Art. No. 7734 or 9385 for flash chromatography). Rf values were measured on Silica gel 60 (Merck, Art. No. 5715) plates using the following TLC systems: A) Benzene -acetone (3 : 1), B) chloroform -methanol (5 : 1), C) chloroform-methanol -28% coned ammonia (15 : 1 :0.1). Spots on TLC plate were detected by UVabsorption and by heating at 100°C after spraying with coned sulfuric acid.
Synthesis of 1 9-Deformyl-4/-deoxydesmycosin (10) The synthesis of compound 10 is shown in Fig. 1 . Desmycosin (1) (10 g) and (Ph3P)3RhCl (12 g) were dissolved in 150 ml of dry benzene and refluxed for 6 hours under an argon atmosphere. The reaction mixture was evaporated and washed with acetone, then the resulting yellow precipitate was filtered off and the filtrate was evaporated under reduced pressure. The residue was dissolved in benzene (100 ml) and extracted three times with 0.4 n aqueous hydrochloric acid (150 ml each). The extract was washed with w-hexane, then adjusted to pH 9 to 9.5 by adding coned ammonia and extracted with chloroform (500 ml). The extract was filtered through WhatmanIPS filter paper and then evaporated in vacuo to obtain crude 19-deformyldesmycosin (6) (7.5 g). To thus obtained compound 6 (5 g) dissolved in dry dichloromethane (100 ml), dry pyridine (4.75 ml) and chlorotrimethylsilane (6.8 ml) were added under ice-cooling and the mixture was stirred for 2 hours at 5 to 10°C. Ice-water (200 ml) was added and the reaction mixture was adjusted to pH 9 to 9.5 with 7%aqueous ammonia, and extracted with chloroform (200 ml). The extract was washed with brine, dried over anhydrous magnesium sulfate and then evaporated in vacuo to yield a mixture of 19-deformyl-3,2',4"-tri-<9-trimethylsilyldesmycosin (7) and a small amount of 19-deformyl-3,2^4^4''-tetra-0-trimethylsilyldesmycosin. To the mixture (5.5 g) dissolved in dry pyridine (55 ml), methane sulfonylchloride (2.1 ml) was added under ice-cooling and the mixture was stirred at 0 to 5°C for 4 hours. The reaction mixture was poured into ice-water (900 ml) and adjusted to pH 9 to 9.5 with 7% aqueous ammonia. The resulting precipitate was collected by filtration and dissolved in chloroform (100 ml) then washed with brine. The organic layer was dried over anhydrous magnesiumsulfate and concentrated to dryness in vacuo to obtain crude 1 9-deformyl-4/-O-methanesulfonyl-3,2/,4//-tri-O-trimethylsilyldesmycosin (8) as the major product. To the above crude mixture dissolved in dry methyl ethyl ketone (50 ml), sodium iodide (2.2 g) was added, and the mixture was stirred at 80°C for 1.5 hours. The reaction mixture was concentrated under reduced pressure and added to water (200 ml), adjusted to pH 9 to 9.5 by adding 7% aqueous ammonia, then extracted with chloroform (200 ml). The organic layer was washed with aqueous sodium thiosulfate and brine, filtered through WhatmanIPS filter paper and evaporated in vacuo. The mixture was dissolved in 0.2 n aqueous hydrochloric acid (100 ml) -acetonitrile (100 ml) and stirred for 2 hours at room temperature. The reaction mixture was adjusted to pH 9 to 9.5 with coned ammonia and extracted twice with chloroform (200 ml each). The extract was washedwith brine and dried over anhydrous magnesiumsulfate, then evaporated to dryness under reduced pressure to give a crude mixture of 19-deformyl-4/-deoxy-4/-iododesmycosin (9) and a small amount of 19-deformyldesmycosin (6). The residue was dissolved in a small amount of chloroform and applied to a silica gel column (silica gel; 80 g). Elution was carried out with a mixture of chloroform and methanol (100 : 1, 800 ml then 10 : 1). Each fraction (100 ml) was examined by silica gel TLCand the fractions showing a spot at Rf 0.49 (system C) were collected and evaporated to give compound 9 (3.5 g). The white powder (760 mg) obtained from the fractions showing Rf 0.34 (system C) was recovered as 19-deformyldesmycosin (6). Compound 9 thus obtained was dissolved in dry benzene (50 ml) and reacted with tri(/z-butyl)stannane (2.1 ml) in the presence of 2,2'-azobis(isobutyronitrile) (15 mg) under an argon atmosphere at 80°C for 1 hour. The reaction mixture was extracted three times with 0.4 n aqueous hydrochloric acid (100 ml each). The combined aqueous layer was washed with «-hexane, then adjusted to pH 9 to 9.5 with coned ammonia and extracted with chloroform (300 ml). The extract was filtered through Whatman IPS filter paper then evaporated in vacuo and purified by flash column chromatography (silica gel; 60 g), developing with chloroformmethanol (60 : 1) to yield a white crystalline powder of 19-deformyl-4'-deoxydesmycosin (10) (2.72 g, yield 55.6% from 6): MP 118-120°C; Rf0.49 (system C); [a]g +9.5°(c 1.0, CHC13); UV^a°xH nm (e) 281 (20,000); IR (KBr) cm "1 3480, 2970, 2930, 1710, 1675, 1620, 1590, 1455, 1375, 1355, 1310, 1270, 1125, 1070, 980, 955, 890, 855, 835, 810, 750; chemical Preparation of 1 9-Deformyldesmycosin (6) To desmycosin (1) (2.5 g) dissolved in dry dichloromethane (25 ml), acetic anhydride (1.53 ml) 1 9-Deformyl-4/-deoxydesmycosin (10)
Nal, MeCOEt, 80°C, h) aq CH3CN-HCl, i) Bu3SnH, benzene, 80°C. JUNE 1989 was added and the mixture was stirred for 1 hour at room temperature. The reaction mixture was added to ice-water (50 ml), adjusted to pH 9 to 9.5 by adding 7 % aqueous ammonia, and then extracted with chloroform (50 ml). The extract was filtered through WhatmanIPS filter paper and evaporated to dryness to obtain 2',4'-di-O-acetyldesmycosin (2) To compound 2 dissolved in acetone (15 ml) 0.3 n aqueous sulfamic acid (20.3 ml) and 0.2n aqueous sodium chlorite (18 ml) were added under ice-cooling and the mixture was stirred for 1 hour at room temperature. The reaction mixture was neutralized by adding 7% aqueous ammoniaand extracted three times with chloroform (50 ml each). The combined organic layer was washed with brine, dried over anhydrous magnesiumsulfate and concentrated to dryness in vacuo to give crude 2',4'-di-<9-acetyl-19-carboxy-19-deformyldesmycosin (3) . The residue was chromatographed on a silica gel column (50g) and developed with chloroform -methanol (7 : 1) to yield a white powder of To compound 3 (500 mg) dissolved in dimethoxyethane (5 ml), triethylamine (0.08 ml) and isobutyl chloroformate (0.0745,ml) were added under ice-salt-cooling and kept at 0 to -3°C for 5 minutes and then iV-hydroxypyridine-2-thione (87.5 mg) was added and the mixture was stirred for 5 minutes then allowed to react at room temperature for 15 minutes. To this reaction mixture thiophenol (0.118 ml) and 2,2/-azobis(isobutyronitrile) (19 mg> were added and the mixture was heated at 90°C under an argon atmosphere for 2 hours. The reaction mixture was concentrated in vacuo and dissolved in chloroform (100 ml) then washed with saturated aqueous sodium bicarbonate. The organic layer was separated and dehydrated by a WhatmanIPS phase-separator and evaporated to dryness under reduced pressure to obtain crude 2/,4'-di-0-acetyl-19-deformyldesmycosin (5). The residue was purified by silica gel flash column chromatography (silica gel; 20 g), developing with a mixture of benzene and acetone (12 : 1) to yield a white powder of compound 5 (255 mg, yield 53.7% from 3). This compound 5 dissolved in methanol (5 ml) was stirred at 55°C for 16 hours and evaporated in vacuo to afford 19-deformyldesmycosin (6) in quantitative yield: MP 118~121°C; Rf 0.34 (system C); [a]2D°+2.6°(c 1.0, CHC13); UV yS°xH nm (s) 282 (22,500); CI-MS m/z 744 (M+H), 174; IR (KBr) cm "1 3450, 2970, 2930, 1710, 1670, 1620, 1590, 1460, 1410, 1375, 1355, 1310, 1260, 1165, 1070, 1005, 980, 955, 900, 860, 835, 810, 700 Isolation of 1 9-Deformyl-3,2/,4//-tri-<9-trimethylsilyldesmycosin
A crude mixture (550 mg) of compound 7 as obtained during the synthesis of compound 10 described above, was applied to a silica gel (6 g) column and eluted with benzene -acetone (30 : 1). The fractions (10 ml) showing a spot at Rf 0.43 (system A) were collected and evaporated in vacuo to obtain amorphous compound 7 (230 mg): [a]2D°-3.4°(c 1.0, CHC13); UV ;t££? nm (e) 283 (21,600); CI-MS m\z 960 (M+H), 246; IR (KBr) cm ' 1 3450, 3050, 2960, 2940 (sh), 1740, 1680, 1590, 1450, 1380, 1360 (sh), 1320, 1260, 1170, 1100, 1080 (sh) 
Results and Discussion
Synthesis of 1 9-Deformyl-4'-deoxydesmycosin (10) Desmycosin (1) was refluxed in benzene with a stoichiometric amount of Wilkinson's catalyst ((Ph3P)3RhCl) to obtain 19-deformyldesmycosin (6) in 70 to 80% yield as a single isolatable product. This very simple and high-yield deformylation process is the most desirable method, but Wilkinson's catalyst is too expensive to use for large scale preparation. Therefore a new route for the deformylation was investigated. Reductive decarboxylation6) by the Barton reaction of the 19-carboxyl derivative prepared from compound1 was accomplished in the following manner. The hydroxyl groups at the C-2' and C-4' positions of compound 1 were easily acetylated with acetic anhydride at room temperature to afford a quantitative yield of I'^'-di-O-acetyldesmycosin (2) . The aldehyde at the C-19 position in compound2 was readily oxidized to the corresponding carboxyl group at ambient temperature using NaClO2as an oxidant and sulfamic acid as a scavenger7), to give I'^'-di-O-acetyl-^-deformyl-^-carboxydesmycosin (3) in 80 to 90% yield. Compound 3 was converted in situ to the decarboxylated derivative, 2',4'-di-0-acetyl-19-deformyldesmycosin (5), in good yield by heating the thioester derivative (4) prepared from compound 3 and iV-hydroxypyridme-2-thione with thiophenol or triphenylmethylmercaptan as a hydrogen donor. Deacetylation of compound 5 was achieved in hot methanol to give compound 6 in quantitative yield. Successive in- Table 1 .^NMRchemical shiftsa for 19-deformyl-4'-deoxydesmycosin (10) and desmycosin (1).
Chemical shift (ppm) Values in ppm from Me4Si ; determined from a 2D homonuclear shift-correlated (COSY)experiment. Assignmentsare based on a^C-1!! shift-correlated 2DNMR spectrum.
vestigation showed that selective trimethylsilylation of the three hydroxyl groups at the C-3, C-2' and C-4" positions of compound 6 was performed by reacting with 6 to 8 equivalents of chlorotrimethylsilane in the presence of pyridine in an excellent yield. Since the 19-deformyl-3,2/,4/'-tri-<9-trimethylsilyldesmycosin (7) thus obtained was not very stable, the reaction mixture was carried forward to the next step without further purification. Deoxygenation of the C-4 hydroxyl group in mycaminose has already been accomplished8»0). In our hands, compound7 was reacted with methanesulfonyl chloride in the presence of triethylamine or pyridine at 0 to 5°C to give the corresponding 4'-0-sulfonyl derivative (8). Successive iodination of compound8 with sodium iodide and reductive deiodination with tri(«-butyl)stannane, gave the 4'-deoxy derivative (9). Treatment of compound 9 with aqueous acid resulted in removal of the trimethylsilyl group and yielded compound 10 (yield 41.6 % from 1).
The structure of compound 10 was elucidated by mass spectrometry, *H NMR (Table 1 ) and 13C NMR (Table 2 ) spectral evidence including^^H correlation spectroscopy (COSY) and^-"C COSYspectra.
In Vitro Activity The antimicrobial activity (MIC) of compound 10 was compared with that of 19-deformyldesmycosin (6) and erythromycin and clindamycin. As shown in Table 3 , among the macrolides tested, compound10 showed the best activity against Staphylococcus aureus including a macrolide-resistant strain, but showed less activity against Enterococcus faecalis and Streptococcus agalactiae. Com- Table 3 . Antimicrobial activity of compounds 10 and 6 compared with that of desmycosin (1) EMand clindamycin were purchased from Sigma Chemical Companyand their potencies were corrected with the standard samples from the National Institute of Health of Japan. Determination : Bioassay, paper-disk method (Micrococcus luteus), plotting : meanvalue±SE.
pound 10 also showed the best antimicrobial activity against Mycoplasma pneumoniae and anaerobic bacteria (Table 4) . Thus, deformylation of the aldehyde function resulted in a great increase in in vitro activity.
In Vivo Activity In vivo antimicrobial activity against experimental infections caused by S. aureus Smith, Streptococcus pyogenes S-23 and Streptococcus pneumoniae DP-III was evaluated in mice. As shown in Table 5 , compound 6 was as effective as erythromycin (EM) but its 4/-deoxy derivative, 19-deformyl-4/-deoxydesmycosin (10), was highly effective when administered orally. The PD50 value10) of compound 10 was 1/4 to 1/7 of that ofEM. These results show that deoxygenation of the 4/-hydroxyl group enhances not only in vitro activity but also in vivo activity dramatically.
Blood Levels Compounds 10 and 6, EMand 4/-deoxydesmycosin (ll)8) were given orally to laboratory animals and their blood levels (plasma levels in beagle dogs) were compared as shown in Fig. 2 . The blood levels of compounds10 and 6 were exceedingly high in mice compared with those of compoundll and EM. In hamsters, the blood level of compound 10 was much higher than that of compound 6. This superior bioavailability of compound10 was also shown in beagle dogs. The maximum concentration (Cmax) of compound 10 was 2.94^g/ml even when administered at a 10-mg/kg dose. TLCanalysis of the blood of mice showed no detectable metabolite of compound10, 6 or ll.
Toxicity
Compound10 was given intraperitoneally to Sic ddY mice (male, n=5) at a 100-mg/kg dose to determine if it has hepatic toxicity. It was tested for subacute toxicity (14 days) in ICR JCL mice (male, n=7) by oral administration of a 500-mg/kg dose and a 1,000-mg/kg dose. No appreciable abnormalities were detected in the blood constituents or by pathological observation.
Conclusion
As previously reported53, modification of the aldehyde function of desmycosin (1) has yielded a series of macrolide derivatives with increased oral efficacy and bioavailability. In consideration of the structure of mycinamicins, we have investigated deformylation of the aldehyde group and deoxygenation of the 4'-hydroxyl group in compound 1 and we found effective methods for these investigations as described above.
19-Deformyldesmycosin (6) possessed greater in vitro activity and in vivo efficacy than compound 1. The 4'-deoxy derivative of compound 6, 19-deformyl-4/-deoxydesmycosin (10), however, showed much more increased in vivo activity and greater bioavailability after oral administration. Thus, the deoxygenation of the C-4 hydroxyl group in mycaminose enhanced not only in vitro activity but also in vivo efficacy.
Concerning the increased in vivo activity caused by the conversion of the aldehyde group to a hydrophobic group, other workers suggested that the aldehyde group would be a site of rapid metabolism and its modification to a less rapidly metabolized substituent would result in greater bioavailability^. In the case of compoundll, after oral administration to mice, however, no appreciable metabolites were detected, so we suggest that this greatly enhanced bioavailability of compounds 10 and 6 is caused by their increased absorption and decreased excretion rate.
These results suggest the possibility of clinical use for 19-deformyl-4'-deoxydesmycosin (10).
Further investigation is nowin progress.
